Lifecore Biomedical (LFCR) agreed to be acquired by Webster Equity Partners for $6.28 per share in cash plus contingent value rights, valuing the deal up to $663.7 million. The cash consideration represents a 49.5% premium to the last closing price. Stock resumed trading and surged 58% to $6.62.
Definitive merger agreement signed September 28, 2026.
Cash consideration: $6.28 per common share.
CVR: one non-tradable per share, up to $160 million aggregate.
Series A preferred: conversion amount (approx. $6.53 per common equivalent as of June 30, 2026) plus CVRs.
Premium: 49.5% on cash, 130.2% on full CVR payout.
Total deal value: up to $663.7 million.
FREE ACCOUNT · NO CARD
The headline and the read are open. The reasons are one free account away, on every story.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
WHY IT MATTERS••••••••••Market transmission and exposed assetsBULL / BEAR CASE•••• / ••••Competing evidence, edited togetherNEWS ON PRICE••.•% reactionConfirmation versus SPY and sectorWHAT TO WATCH•• catalystsThe facts that can change the read
BORSAPLUSWhy it matters · Bull and bear case · Reaction against SPY and the sector · What to watch
